1일 전부터 시작된 복통과 구토로 내원한 33세 남자
A 33-Year-Old Man Presented with Abdominal Pain and Vomiting Starting a Day Ago
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are expanding their role beyond the glucose-lowering effects to include reducing body weight and managing the risk of cardiovascular and renal diseases. Accordingly, the number of people with type 2 diabetes using these medications is rapidly increasing. To minimize the potential side effects and ensure safer use, it’s essential to time prescriptions correctly and educate patients thoroughly. Special caution is required when prescribing to patients with symptomatic and severe hyperglycemia who require insulin. Patients should be instructed to discontinue the medication immediately if they experience symptoms like abdominal pain, nausea, or vomiting. Moreover, if a patient taking SGLT-2 inhibitors is in poor general condition, diagnostic tests for euglycemic diabetic ketoacidosis should be performed, even if the blood glucose levels are not elevated. In such cases, prompt fluid resuscitation and intravenous insulin treatment should be initiated. Additionally, the risk of diabetic ketoacidosis may increase under acute stress conditions such as severe infections, trauma, or major surgery. Therefore, it may be necessary to discontinue SGLT-2 inhibitors and switch to other medications for blood glucose management in these situations.
Abstract
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are expanding their role beyond the glucose-lowering effects to include reducing body weight and managing the risk of cardiovascular and renal diseases. Accordingly, the number of people with type 2 diabetes using these medications is rapidly increasing. To minimize the potential side effects and ensure safer use, it’s essential to time prescriptions correctly and educate patients thoroughly. Special caution is required when prescribing to patients with symptomatic and severe hyperglycemia who require insulin. Patients should be instructed to discontinue the medication immediately if they experience symptoms like abdominal pain, nausea, or vomiting. Moreover, if a patient taking SGLT-2 inhibitors is in poor general condition, diagnostic tests for euglycemic diabetic ketoacidosis should be performed, even if the blood glucose levels are not elevated. In such cases, prompt fluid resuscitation and intravenous insulin treatment should be initiated. Additionally, the risk of diabetic ketoacidosis may increase under acute stress conditions such as severe infections, trauma, or major surgery. Therefore, it may be necessary to discontinue SGLT-2 inhibitors and switch to other medications for blood glucose management in these situations.
참고문헌 (18)
- Bell RM, "SGLT2 inhibitors : hypotheses on the mechanism of cardiovascular protection", Lancet Diabetes Endocrinol, 6, pp.435~437 (2018)
- Muskiet MHA, "Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes", Lancet Diabetes Endocrinol, 4, pp.188~189 (2016)
- ElSayed NA, "Pharmacologic approaches to glycemic treatment : standards of care in diabetes-2023", Diabetes Care, 46(Suppl 1), pp.S140~S157 (2023)
- 최종한, "2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association", Diabetes and Metabolism Journal, 47(5), pp.575~594 (2023), 대한당뇨병학회[DOI]
- Youn Jong-Chan, "Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment", International Journal of Heart Failure, 5(2), pp.66~81 (2023), 대한심부전학회[DOI]
- Navaneethan SD, "Diabetes management in chronic kidney disease : synopsis of the KDIGO 2022 clinical practice guideline update", Ann Intern Med, 176, pp.381~387 (2023)
- Fralick M, "Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor", N Engl J Med, 376, pp.2300~2302 (2017)
- Colacci M, "Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes : a systematic review and meta-analysis", Can J Diabetes, 46, pp.10~15 (2022)
- Liu J, "Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes : a systematic review and meta-analysis of randomized controlled trials", Diabetes Obes Metab, 22, pp.1619~1627 (2020)
- Ogawa W, "Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors : possible mechanism and contributing factors", J Diabetes Investig, 7, pp.135~138 (2016)
- Taylor SI, "SGLT2 inhibitors may predispose to ketoacidosis", J Clin Endocrinol Metab, 100, pp.2849~2852 (2015)
- Modi A, "Euglycemic diabetic ketoacidosis : a review", Curr Diabetes Rev, 13, pp.315~321 (2017)
- Chow E, "Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors", BMJ Open Diabetes Res Care, 11, pp.e003666~ (2023)
- Dhatariya KK, "Guidelines for management of diabetic ketoacidosis : time to revise?", Lancet Diabetes Endocrinol, 5, pp.321~323 (2017)
- Jhaveri U, "Sodium-glucose cotransporter-2 inhibitors and euglycaemic diabetic ketoacidosis in the perioperative period : case report", Cureus, 11, pp.e5455~ (2019)
- Bamgboye AO, "Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors : a review", Eur J Clin Pharmacol, 77, pp.651~657 (2021)
- ElSayed NA, "Diabetes care in the hospital : standards of care in diabetes-2023", Diabetes Care, 46(Suppl 1), pp.S267~S278 (2023)
- Dhatariya KK, "The management of diabetic ketoacidosis in adults-an updated guideline from the Joint British Diabetes Society for Inpatient Care", Diabet Med, 39, pp.e14788~ (2022)